The Patent Finder

Epitech Group S.P.A.

16 patents currently held · Updated Nov 15, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Sep 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 21, 2027
    The maintenance fee for Composition of N-palmitoyl-ethanolamide and Rutin in co-micronized form (US 11,819,511) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,470,373Composition containing ultra-micronized palmitoyl-ethanolamide
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,663,701Compositions containing ultra-micronized palmitoyl-ethanolamide
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,402,818Use of amides of mono- and dicarboxylic acids in the treatment of renal diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,546,352Pharmacological preparation for topical use containing N-palmitoyl-vanillamide
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,512,091Compositions and methods for the modulation of specific amidases for N-acylethanolamines for use in the therapy of inflammatory diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,522,192Polyethylene glycol derivatives of palmitoylethanolamide and analogous acylethanolamides
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,399,031Combined use of amides of mono- and dicarboxylic acids and silymarin in the treatment of renal diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,364,678Pharmaceutical composition comprising palmitoylethanolamide and L- Acetylcarnitine
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,668,986Ophthalmic, intra-articular or intravesical preparations containing N-acyl-ethanolamines
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,801,836Using palmitoylethanolamide in combination with opioids
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 16 patents shown.
Pro members see all 16.
Pro members: see all 16 patents
Also on record, not counted in the 16: 2 patents in force now held by others · 3 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 2 abandoned · 10 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited